2020
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials
Saba C, Clifford C, Burgess K, Phillips B, Vail D, Wright Z, Curran K, Fan T, Elmslie R, Post G, Thamm D. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Veterinary And Comparative Oncology 2020, 18: 763-769. PMID: 32346934, PMCID: PMC7754483, DOI: 10.1111/vco.12605.Peer-Reviewed Original ResearchConceptsLarge cell lymphomaCell lymphomaOverall median progression-free intervalMedian progression-free intervalAdverse event evaluationAdverse event profileMinute intravenous infusionProgression-free intervalProspective clinical trialsT-cell immunophenotypeOverall response rateSubstantial antitumour activityDrug-resistant relapseRelapsed subjectsSupportive treatmentUntreated dogsUntreated lymphomaConcurrent corticosteroidsDosage adjustmentPulmonary fibrosisEvent profileGastrointestinal originGroup criteriaIntravenous infusionInferior outcomes
2017
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
Thamm D, Vail D, Post G, Fan T, Phillips B, Axiak‐Bechtel S, Elmslie R, Klein M, Ruslander D. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. Journal Of Veterinary Internal Medicine 2017, 31: 872-878. PMID: 28370378, PMCID: PMC5435064, DOI: 10.1111/jvim.14700.Peer-Reviewed Original ResearchConceptsProgression-free intervalMulticentric lymphomaComplete responseOverall median progression-free intervalMedian progression-free intervalMulticenter prospective clinical trialSubstantial single-agent activityAdverse effect profileAssessment of remissionMost adverse eventsProspective clinical trialsSingle-agent activityLong-term outcomesOverall response rateCanine multicentric lymphomaDermatologic AEsHematologic AEsClinicopathological evaluationAdverse eventsChemotherapy combinationsCombination chemotherapyTreatment visitsUntreated lymphomaEffect profilePulmonary fibrosis
2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
London C, Gardner H, Mathie T, Stingle N, Portela R, Pennell M, Clifford C, Rosenberg M, Vail D, Williams L, Cronin K, Wilson-Robles H, Borgatti A, Henry C, Bailey D, Locke J, Northrup N, Crawford-Jakubiak M, Gill V, Klein M, Ruslander D, Thamm D, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLOS ONE 2015, 10: e0124889. PMID: 25923466, PMCID: PMC4414350, DOI: 10.1371/journal.pone.0124889.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, MetronomicAmputation, SurgicalAnimalsBone NeoplasmsCarboplatinCyclophosphamideDiarrheaDisease-Free SurvivalDog DiseasesDogsDrug Therapy, CombinationFemaleIndolesKaplan-Meier EstimateMaleNeutropeniaOsteosarcomaPiroxicamProspective StudiesPyrrolesRegression AnalysisTreatment OutcomeConceptsDisease-free intervalMedian disease-free intervalCarboplatin chemotherapyMetastatic diseaseOverall survivalControl dogsMaintenance therapyAppendicular osteosarcomaMedical conditionsSurvival rateTherapy-associated adverse eventsGross metastatic diseaseMedian overall survivalOutcome of dogsProspective clinical trialsYear survival rateMulti-institutional studyPiroxicam therapyCyclophosphamide therapyAdverse eventsPatient demographicsSupportive careStudy entryMetronomic treatmentClinical trials